UFIS-SWE-IG
0.1.0 - ci-build

UFIS-SWE-IG, published by UNICOM. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/ufis-swe-ig/ and changes regularly. See the Directory of published versions

: Levaxin-200mg-Tablet-SE-BS-ING - XML Representation

Raw xml | Download



<Ingredient xmlns="http://hl7.org/fhir">
  <id value="Levaxin-200mg-Tablet-SE-BS-ING"/>
  <meta>
    <profile
             value="http://unicom-project.eu/fhir/StructureDefinition/PPLIngredient"/>
  </meta>
  <text>
    <status value="generated"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: Ingredient Levaxin-200mg-Tablet-SE-BS-ING</b></p><a name="Levaxin-200mg-Tablet-SE-BS-ING"> </a><a name="hcLevaxin-200mg-Tablet-SE-BS-ING"> </a><a name="hcLevaxin-200mg-Tablet-SE-BS-ING-en-US"> </a><p><b>status</b>: Active</p><p><b>for</b>: </p><ul><li><a href="MedicinalProductDefinition-Levaxin-200mg-Tablet-SE-BS-MPD.html">MedicinalProductDefinition: identifier = http://ema.europa.eu/fhir/mpId#SE-XXXXXXXXX-00021055,http://ema.europa.eu/fhir/eurdId#1860; domain = Human use; status = Current; combinedPharmaceuticalDoseForm = Tablet; indication = Hypotyreos av alla former t ex vid autoimmun tyreoidit, efter radiojod- och kirurgisk terapi av hypertyreos och vid progressiv oftalmopati när den är förenad med hypotyreos.  Som tillägg till tyreostatika vid långtidsbehandling av hypertyreos och vid preoperativ kombinationsbehandling av hypertyreos. Tyreoideacancer. Myxödemkoma.; legalStatusOfSupply = Medicinal product subject to medical prescription; classification = levothyroxine sodium</a></li><li><a href="ManufacturedItemDefinition-Levaxin-200mg-Tablet-SE-BS-MID.html">ManufacturedItemDefinition: status = active; manufacturedDoseForm = Tablet; unitOfPresentation = Tablet</a></li><li><a href="AdministrableProductDefinition-Levaxin-200mg-Tablet-SE-BS-APD.html">AdministrableProductDefinition: status = active; administrableDoseForm = Tablet</a></li></ul><p><b>role</b>: <span title="Codes:{https://spor.ema.europa.eu/v1/lists/100000072050 100000072072}">Active</span></p><blockquote><p><b>substance</b></p><h3>Codes</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Concept</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{https://spor.azure-api.net/sms/api/v2/SubstanceDefinition 100000145050}">Anhydrous levothyroxine sodium</span></td></tr></table><blockquote><p><b>strength</b></p><p><b>presentation</b>: 205.7 microgram(s)<span style="background: LightGoldenRodYellow"> (Details: 100000110633  code100000110656 = '100000110656')</span>/1 tablet<span style="background: LightGoldenRodYellow"> (Details: 200000000014  code200000002152 = '200000002152')</span></p><blockquote><p><b>referenceStrength</b></p><h3>Substances</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Concept</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{https://spor.azure-api.net/sms/api/v2/SubstanceDefinition 100000086128}">Levothyroxine</span></td></tr></table><p><b>strength</b>: 200 microgram(s)<span style="background: LightGoldenRodYellow"> (Details: Unit of Measurement EMA  code100000110656 = 'microgram(s)')</span>/1 tablet<span style="background: LightGoldenRodYellow"> (Details: 200000000014  code200000002152 = '200000002152')</span></p></blockquote></blockquote></blockquote></div>
  </text>
  <status value="active"/>
  <for>🔗 
    <reference
               value="MedicinalProductDefinition/Levaxin-200mg-Tablet-SE-BS-MPD"/>
  </for>
  <for>🔗 
    <reference
               value="ManufacturedItemDefinition/Levaxin-200mg-Tablet-SE-BS-MID"/>
  </for>
  <for>🔗 
    <reference
               value="AdministrableProductDefinition/Levaxin-200mg-Tablet-SE-BS-APD"/>
  </for>
  <role>
    <coding>
      <system value="https://spor.ema.europa.eu/v1/lists/100000072050"/>
      <code value="100000072072"/>
      <display value="Active"/>
    </coding>
  </role>
  <substance>
    <code>
      <concept>
        <coding>
          <system
                  value="https://spor.azure-api.net/sms/api/v2/SubstanceDefinition"/>
          <code value="100000145050"/>
          <display value="Anhydrous levothyroxine sodium"/>
        </coding>
      </concept>
    </code>
    <strength>
      <presentationRatio>
        <numerator>
          <value value="205.7"/>
          <unit value="microgram(s)"/>
          <system value="http://spor.ema.europa.eu/v1/lists/100000110633"/>
          <code value="100000110656"/>
        </numerator>
        <denominator>
          <value value="1"/>
          <unit value="tablet"/>
          <system value="http://spor.ema.europa.eu/v1/lists/200000000014"/>
          <code value="200000002152"/>
        </denominator>
      </presentationRatio>
      <referenceStrength>
        <substance>
          <concept>
            <coding>
              <system
                      value="https://spor.azure-api.net/sms/api/v2/SubstanceDefinition"/>
              <code value="100000086128"/>
              <display value="Levothyroxine"/>
            </coding>
          </concept>
        </substance>
        <strengthRatio>
          <numerator>
            <value value="200"/>
            <unit value="microgram(s)"/>
            <system value="https://spor.ema.europa.eu/v1/lists/100000110633"/>
            <code value="100000110656"/>
          </numerator>
          <denominator>
            <value value="1"/>
            <unit value="tablet"/>
            <system value="http://spor.ema.europa.eu/v1/lists/200000000014"/>
            <code value="200000002152"/>
          </denominator>
        </strengthRatio>
      </referenceStrength>
    </strength>
  </substance>
</Ingredient>